hepatology Archives -

Advance Combination Therapies, Outline Clinical Endpoints & Understand the Immunology Perspective to Achieve Functional Cures for Chronic Hepatitis

Welcome to the 2nd Chronic HBV Drug Development Summit

https://pharmaphorum.com/events/welcome-to-the-2nd-chronic-hbv-drug-development-summit/

News/ News/ R&D

Madrigal sings praises of NASH drug resmetirom

Phil Taylor hepatology, Madrigal Pharmaceuticals, NASH 0 Comment

After a phase 3 trial win, Madrigal Pharmaceuticals reckons it could succeed where so many other companies have

Madrigal sings praises of NASH drug resmetirom

https://pharmaphorum.com/news/madrigal-sings-praises-of-nash-drug-resmetirom/

News/ News/ R&D

Bayer trumpets $1bn CRISPR deal with Mammoth Bio

Phil Taylor Bayer, CRISPR, gene editing, hepatology, Mammoth Biosciences, partnering 0 Comment

Bayer has bolstered its cell and gene therapy platform by securing access to a CRISPR-based gene-editing platform developed

Bayer trumpets $1bn CRISPR deal with Mammoth Bio

https://pharmaphorum.com/news/bayer-trumpets-crispr-deal-mammoth-bio/

News/ News/ R&D

Ipsen places €480m bet on Genfit’s liver drug elafibranor

Phil Taylor elafibranor, Genfit, hepatology, Ipsen, partnering, primary biliary cholangitis 0 Comment

Genfit was hit hard last year when it abandoned a phase 3 programme for elafibranor in non-alcoholic steatohepatitis

Ipsen places €480m bet on Genfit’s liver drug elafibranor

https://pharmaphorum.com/news/ipsen-places-e480m-bet-on-genfits-liver-drug-elafibranor/

Market Access/ News/ News

Intercept’s travails continue as it pulls NASH drug filing in EU

Phil Taylor EU, hepatology, Intercept Pharmaceuticals, NASH, regulatory 0 Comment

Already scrambling to refile its obeticholic acid (OCA) drug for non-alcoholic steatohepatitis (NASH) after the FDA rejected it

Intercept’s travails continue as it pulls NASH drug filing in EU

https://pharmaphorum.com/news/intercepts-travails-continue-as-it-pulls-nash-drug-filing-in-eu/

Digital/ News/ News

Digital health firm ChronWell raises $6m for liver disease toolkit

Phil Taylor ChronWell, digital, digital health, hepatology, LIVErHEALTHY, NASH, remote care 0 Comment

US remote healthcare specialist ChronWell has raised $6 million from investors that will be used to accelerate the

Digital health firm ChronWell raises $6m for liver disease toolkit

https://pharmaphorum.com/news/digital-health-firm-chronwell-raises-6m-for-liver-disease-toolkit/

News/ News/ R&D

NGM craters after dropping mid-stage NASH candidate aldafermin

Phil Taylor fibrosis, hepatology, NASH, NGM Bio 0 Comment

Shares in NGM Biopharma have plummeted after the US biotech said it would abandon development of aldafermin in

NGM craters after dropping mid-stage NASH candidate aldafermin

https://pharmaphorum.com/news/ngm-craters-after-dropping-mid-stage-nash-candidate-aldafermin/

News/ News/ R&D

Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit

Phil Taylor Diabetes, Dicerna, gene silencing, hepatology, NASH, Novo Nordisk, RNAi 0 Comment

Two years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a

Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit

https://pharmaphorum.com/news/novo-nordisks-gene-silencing-alliance-with-dicerna-bears-first-fruit/

News/ News/ R&D

Gilead and Novo plot next steps after trial data from NASH combo

Richard Staines Gilead, hepatology, NASH, Novo Nordisk, semaglutide 0 Comment

Gilead and Novo Nordisk have announced their drug combinations for the fatty liver disease known as NASH checked

Gilead and Novo plot next steps after trial data from NASH combo

https://pharmaphorum.com/news/gilead-and-novo-plot-next-steps-after-encouraging-data-from-nash-combo/

Trending

hepatology

Login